Thus, the only CAR-T cell therapies approved for clinical practice by regulatory agencies are anti-CD19 CAR-T cells for CD19+ B-cell lymphoproliferative malignancies (tisagenlecleucel (KymriahTM), Axicabtagene ciloleucel (YescartaTM), Brexucabtagene autoleucel (TecartusTM), Lisocabtagene maraleucel (BreyanziTM), and anti-BCMA CAR-T cells for multiple myelomas (Idecabtagene vicleucel (Abecma®)) [35]. Here, CD19 is linked to plasma cell myeloma.